Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 19, 2018 08:45 ET | Source: RespireRX Pharmaceuticals Inc.

Advancing Dronabinol Obstructive Sleep Apnea Program with Letter of Intent for Co-Development and Supply Agreement with Noramco, Inc.

Glen Rock, N.J., June 19, 2018 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), is pleased to announce that on June 13, 2018, it entered into a letter...
January 08, 2018 08:45 ET | Source: RespireRX Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. to Present at 10th Annual Biotech Showcase™ 2018

CEO to Review completed Phase IIB dronabinol trial for the treatment of Obstructive Sleep Apnea (OSA) and Provide Pipeline update Glen Rock, N.J., Jan. 08, 2018 (GLOBE NEWSWIRE) -- RespireRx...
December 18, 2017 08:45 ET | Source: RespireRX Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. Publishes Compelling Scientific Evidence Demonstrating the Neurobiological Safety of Ampakine CX717 and Justifying Continued Clinical Development

Glen Rock, N.J., Dec. 18, 2017 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), is pleased to announce that a paper detailing the neurobiologic safety...
December 15, 2017 09:00 ET | Source: RespireRX Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. Officers and Directors Elect to Forgive $2,356,733 of Past Due Cash Compensation and Receive Non-Qualified Stock Options to Reduce Balance Sheet Debt

Glen Rock, N.J., Dec. 15, 2017 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC QB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for the treatment of...
November 30, 2017 08:45 ET | Source: RespireRX Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. Announces Publication of Phase 2B PACE Study: Once per Night Treatment with Dronabinol Provides Statistically Significant Improvement in Clinical Measures of Obstructive Sleep Apnea

Glen Rock, N.J, Nov. 30, 2017 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”) announces that the results of the PACE (Pharmacotherapy of Apnea by...

keyboard_arrow_left Previous Page